These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7638008)

  • 21. The immunogenicity of Haemophilus influenzae type b conjugate vaccines in children born to human immunodeficiency virus-infected women. Women and Infants Transmission Study Group.
    Read JS; Frasch CE; Rich K; Fitzgerald GA; Clemens JD; Pitt J; Pelton SI; Hanson IC; Handelsman E; Diaz C; Fowler MG
    Pediatr Infect Dis J; 1998 May; 17(5):391-7. PubMed ID: 9613652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants.
    Lee CY; Thipphawong J; Huang LM; Lee PI; Chiu HH; Lin W; Debois H; Harrison D; Xie F; Barreto L
    Pediatrics; 1999 Jan; 103(1):25-30. PubMed ID: 9917435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period.
    Miller MA; Meschievitz CK; Ballanco GA; Daum RS
    Pediatrics; 1995 Apr; 95(4):522-7. PubMed ID: 7700752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age.
    Avendano A; Ferreccio C; Lagos R; Horwitz I; Cayazzo M; Fritzell B; Meschievitz C; Levine M
    Pediatr Infect Dis J; 1993 Aug; 12(8):638-43. PubMed ID: 8414775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.
    Shinefield HR; Black S; Ray P; Chang I; Lewis N; Fireman B; Hackell J; Paradiso PR; Siber G; Kohberger R; Madore DV; Malinowski FJ; Kimura A; Le C; Landaw I; Aguilar J; Hansen J
    Pediatr Infect Dis J; 1999 Sep; 18(9):757-63. PubMed ID: 10493334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody response of Mexican infants to Haemophilus influenzae type b capsular polyribosylribitol phosphate. Differences between natural and vaccine induced (oligosaccharide-CRM197 conjugated vaccine) immunization.
    Massó F; Paéz A; Arista A; Salmón L; Montaño L
    Arch Med Res; 1996; 27(4):539-45. PubMed ID: 8987192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines.
    Granoff DM; Rathore MH; Holmes SJ; Granoff PD; Lucas AH
    Vaccine; 1993; 11 Suppl 1():S46-51. PubMed ID: 8447176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody responses to four Haemophilus influenzae type b conjugate vaccines.
    Käyhty H; Eskola J; Peltola H; Rönnberg PR; Kela E; Karanko V; Saarinen L
    Am J Dis Child; 1991 Feb; 145(2):223-7. PubMed ID: 1994693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of the Haemophilus influenzae type b capsular polysaccharide conjugate vaccine in children after systemic Haemophilus influenzae type b infections.
    Kaplan SL; Zahradnik JM; Mason EO; Dukes CM
    J Pediatr; 1988 Aug; 113(2):272-7. PubMed ID: 3260943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response.
    Dockrell DH; Poland GA; Steckelberg JM; Wollan PC; Strickland SR; Pomeroy C
    Vaccine; 1999 Jul; 17(22):2779-85. PubMed ID: 10438047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence of antibody responses to Haemophilus influenzae type b polysaccharide conjugate vaccine in children with vertically acquired human immunodeficiency virus infection.
    Gibb D; Giacomelli A; Masters J; Spoulou V; Ruga E; Griffiths H; Kroll S; Giaquinto C; Goldblatt D
    Pediatr Infect Dis J; 1996 Dec; 15(12):1097-101. PubMed ID: 8970219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of four Haemophilus influenzae type b conjugate vaccines in 17- to 19-month-old children.
    Holmes SJ; Murphy TV; Anderson RS; Kaplan SL; Rothstein EP; Gan VN; Granoff DM
    J Pediatr; 1991 Mar; 118(3):364-71. PubMed ID: 1999775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in infancy. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group.
    Black SB; Shinefield HR; Lampert D; Fireman B; Hiatt RA; Polen M; Vittinghoff E
    Pediatr Infect Dis J; 1991 Feb; 10(2):92-6. PubMed ID: 2062620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of two doses of catch-up immunization with Haemophilus influenzae type b conjugate vaccine in Indian children living with HIV.
    Arya BK; Bhattacharya SD; Sutcliffe CG; Saha MK; Bhattacharyya S; Niyogi SK; Moss WJ; Panda S; Das RS; Mallick M; Mandal S
    Vaccine; 2016 Apr; 34(19):2267-74. PubMed ID: 26988256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses.
    Yogev R; Arditi M; Chadwick EG; Amer MD; Sroka PA
    Pediatrics; 1990 Apr; 85(4 Pt 2):690-3. PubMed ID: 2107520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haemophilus influenzae type b-specific antibody in infants after maternal immunization.
    Englund JA; Glezen WP; Thompson C; Anwaruddin R; Turner CS; Siber GR
    Pediatr Infect Dis J; 1997 Dec; 16(12):1122-30. PubMed ID: 9427456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An enzyme-linked immunosorbent assay for quantitation of Haemophilus Influenzae type b polysaccharide-specific IgG1 and IgG2 in human and infant rhesus monkey sera.
    Dolan KT; Staub JM; Schofield TL; Ahonkhai VI; Ellis RW; Vella PP
    J Immunoassay; 1991; 12(4):543-64. PubMed ID: 1806588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine.
    Panpitpat C; Thisyakorn U; Chotpitayasunondh T; Fürer E; Que JU; Hasler T; Cryz SJ
    Bull World Health Organ; 2000; 78(3):364-71. PubMed ID: 10812736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunity to Haemophilus influenzae type b polysaccharide capsule in children with human immunodeficiency virus infection immunized with a single dose of Haemophilus vaccine.
    Peters VB; Sood SK
    J Pediatr; 1994 Jul; 125(1):74-7. PubMed ID: 8021791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of Haemophilus influenzae type B-Neisseria meningitidis group B outer membrane protein complex conjugate vaccine mixed in the syringe with diphtheria-tetanus-pertussis vaccine in young Gambian infants.
    Mulholland EK; Ahonkhai VI; Greenwood AM; Jonas LC; Lukacs LJ; Mink CM; Staub JM; Todd J; Vella PP; Greenwood BM
    Pediatr Infect Dis J; 1993 Aug; 12(8):632-7. PubMed ID: 8414774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.